ArticleHepatology (Baltimore, Md.)2017
Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Immunophenotypic insights into diabetes heterogeneity: The role of CD25-expressing T cells in Ghanaian type 1 diabetes cohorts.Journal of translational autoimmunity · 2026Article
- Revealing the pathogenesis of autoimmune hepatitis and research progress in drug discovery from hepatic immune cells and intercellular communication signaling mechanisms.Frontiers in immunology · 2026Review
- B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.JPGN reports · 2024Article
- Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy.Signal transduction and targeted therapy · 2024Article
- Pien Tze Huang alleviates Concanavalin A-induced autoimmune hepatitis by regulating intestinal microbiota and memory regulatory T cells.World journal of gastroenterology · 2023Article
- Macrophage-mediated tumor-targeted delivery of engineeredActa pharmaceutica Sinica. B · 2022Article
- Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis.Hepatology (Baltimore, Md.) · 2022Article
- Autoimmmune hepatitis.Cellular & molecular immunology · 2022Review
- Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes.Frontiers in pharmacology · 2022Article
- Case Report: Simultaneously Developed Amyopathic Dermatomyositis and Autoimmune Sclerosing Cholangitis - a Coincidence or a Shared Immunopathogenesis?Frontiers in immunology · 2022Article
- RIP3 blockade prevents immune-mediated hepatitis through a myeloid-derived suppressor cell dependent mechanism.International journal of biological sciences · 2022Article
- Activation of AMPKα1 is essential for regulatory T cell function and autoimmune liver disease prevention.Cellular & molecular immunology · 2021Article
- Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.Frontiers in immunology · 2021Review
- Immunopathobiology and therapeutic targets related to cytokines in liver diseases.Cellular & molecular immunology · 2021Review
- Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies.Frontiers in immunology · 2021Review
- Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.Journal of Crohn's & colitis · 2020Article
- Article
- Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients.Frontiers in immunology · 2020Review
- Interleukin-33 Amplifies Human Mast Cell Activities Induced by Complement Anaphylatoxins.Frontiers in immunology · 2020Article
- Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.JHEP reports : innovation in hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Imbalance between T regulatory (Treg) and T effector (Teff) cells is likely to contribute to the induction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability of Tregs to restrain proliferation and effector cytokine production by responders or through conversion of Tregs into T helper type 1 (Th1) or type 17 (Th17) effector lymphocytes. We investigated the effect of Treg skewing on the phenotypic and functional properties of CD4
conclusionTreg skewing confers activated Teff phenotypic and functional properties of T regulatory 1 cells in health and in AIH/AISC, though suppressive function is lost in patients upon proinflammatory challenge; protracted modulation of the inflammatory environment is required to attenuate the effector potential while boosting immunoregulatory properties in Teff. (Hepatology 2017;66:1570-1584).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.